首頁 > 市場調查報告書 > 製藥

生物標記循環系統

市場調查報告書

商品編碼

1922444

日本心臟生物標記市場報告：按類型、檢測施行地點、應用和地區分類（2026-2034年）

Japan Cardiac Biomarkers Market Report by Type (Troponins, Myocardial Muscle Creatine Kinase, Myoglobin, Brain Natriuretic Peptide or NT-proBNP, Ischemia Modified Albumin, and Others), Location of Testing, Application, and Region 2026-2034

出版日期: 2026年01月01日 | 出版商:

IMARC | 英文 121 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2025年，日本心臟生物標記市場規模達7.311億美元。 IMARC Group預測，到2034年，該市場規模將達到13.93億美元，2026年至2034年的複合年成長率（CAGR）為7.43%。心臟病、中風和心臟衰竭等心血管疾病的日益增多，推動了對心臟生物標記的需求，使其能夠用於早期檢測、風險評估和病患監測，從而擴大了市場規模。

心臟生物標記是指在心臟相關疾病發生時釋放到血液中的蛋白質或分子。它們在診斷和監測各種心臟疾病方面發揮著重要作用。典型的心臟生物標記包括肌鈣蛋白、肌酸激酶-MB (CK-MB) 和 B 型鈉尿肽 (BNP)。肌鈣蛋白是心肌損傷的高度特異性指標，對於診斷心肌梗塞至關重要。 CK-MB 是另一種在心肌損傷時升高的酵素。而 BNP 則有助於評估心臟衰竭及其嚴重程度。透過血液檢測測量心臟生物標記物，醫護人員可以檢測和評估心臟問題，確定損傷程度，並制定合適的治療方案。這些生物標記能夠提供有關心臟整體健康狀況的重要資訊，並指南醫療干預以改善患者預後。定期監測心臟生物標記對於控制心臟疾病和預防併發症至關重要。

日本心臟生物標記市場趨勢：

由於幾個關鍵因素，日本心臟生物標記市場預計將顯著成長。首先，包括冠狀動脈疾病和心臟衰竭在內的心血管疾病盛行率不斷上升，顯著推動了對心臟生物標記檢測的需求。此外，該地區人口老化也是一個重要的促進因素。老年族群罹患心臟相關疾病的風險更高，因此對心臟生物標記診斷的需求持續存在。此外，醫療技術的進步和高靈敏度心臟生物標記檢測的廣泛應用提高了心臟疾病檢測的準確性和效率。這不僅改善了患者的治療效果，也促使醫療機構將這些檢測納入常規臨床實務。此外，醫護人員和患者對早期發現和預防心臟病重要性的認知不斷提高，也導致了檢測率的上升。對預防醫學和心臟健康主動監測的日益重視正在推動心臟生物標記市場的發展。最後，政府對心血管研究和診斷工具的支持措施和資金投入也促進了市場擴張。總而言之，這些促進因素共同為心臟生物標記市場在不久的將來持續成長創造了有利環境。

本報告解答的關鍵問題

日本心臟生物標記市場目前發展狀況如何？未來幾年又將如何發展？
新冠疫情對日本心臟生物標記市場產生了哪些影響？
日本心臟生物標記市場按類型是如何分類的？
日本心臟生物標記市場依檢測施行地點分類的組成是怎樣的？
日本心臟生物標記市場按應用領域分類的組成是怎樣的？
請介紹日本心臟生物標記市場價值鏈的各個環節。
日本心臟生物標記市場的主要促進因素和挑戰是什麼？
日本心臟生物標記市場的結構是怎麼樣的？主要參與者有哪些？
日本心臟生物標記市場競爭有多激烈？

Japan cardiac biomarkers market size reached USD 731.1 Million in 2025 . Looking forward, IMARC Group expects the market to reach USD 1,393.0 Million by 2034 , exhibiting a growth rate (CAGR) of 7.43% during 2026-2034 . The increasing prevalence of cardiovascular diseases such as heart attacks, strokes, and heart failure, that require cardiac biomarkers for early detection, risk assessment, and monitoring of patients, is driving the market.

Access the full market insights report Request Sample

Cardiac biomarkers are proteins or molecules released into the bloodstream in response to heart-related conditions. They play a crucial role in diagnosing and monitoring various heart disorders. Common cardiac biomarkers include troponins, creatine kinase-MB (CK-MB), and B-type natriuretic peptide (BNP). Troponins are highly specific indicators of heart muscle damage and are essential in diagnosing heart attacks. CK-MB is another enzyme that rises in response to heart muscle injury. BNP, on the other hand, helps assess heart failure and its severity. Measuring cardiac biomarkers through blood tests allows healthcare professionals to detect and evaluate heart problems, determine the extent of damage, and formulate appropriate treatment plans. These biomarkers provide valuable insights into the overall health of the heart and help guide medical interventions to improve patient outcomes. Regular monitoring of cardiac biomarkers is essential in managing heart conditions and preventing complications.

JAPAN CARDIAC BIOMARKERS MARKET TRENDS:

The cardiac biomarkers market in Japan is poised for substantial growth, driven by several key factors. Firstly, the escalating prevalence of cardiovascular diseases, including coronary artery disease and heart failure, has significantly increased the demand for cardiac biomarker testing. Additionally, the aging regional population is a major driver, as older individuals are at higher risk of cardiac-related issues, creating a sustained need for cardiac biomarker diagnostics. Moreover, advancements in medical technology and the increasing adoption of high-sensitivity cardiac biomarker assays have enhanced the accuracy and efficiency of cardiac disease detection. This has not only improved patient outcomes but also encouraged healthcare providers to incorporate these tests into their routine clinical practices. Furthermore, the growing awareness among both healthcare professionals and patients regarding the importance of early cardiac disease detection and prevention has led to increased testing rates. The emphasis on preventive healthcare and proactive monitoring of cardiac health has bolstered the cardiac biomarkers market. Lastly, supportive government initiatives and funding for cardiovascular research and diagnostic tools have fueled market expansion. Overall, these drivers converge to create a favorable landscape for the cardiac biomarkers market's sustained growth in the foreseeable future.

JAPAN CARDIAC BIOMARKERS MARKET SEGMENTATION:

Type Insights:

To get detailed segment analysis of this market Request Sample
Troponins (T and I)
Myocardial Muscle Creatine Kinase (CK-MB)
Myoglobin
Brain Natriuretic Peptide (BNPs) or NT-proBNP
Ischemia Modified Albumin (IMA)
Others
Troponins (T and I)
Myocardial Muscle Creatine Kinase (CK-MB)
Myoglobin
Brain Natriuretic Peptide (BNPs) or NT-proBNP
Ischemia Modified Albumin (IMA)
Others

Location of Testing Insights:

Laboratory Testing
Point of Care Testing
Laboratory Testing
Point of Care Testing

Application Insights:

Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Others
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Others

Regional Insights:

To get detailed regional analysis of this market Request Sample
Kanto Region
Kansai/Kinki Region
Central/ Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
Kanto Region
Kansai/Kinki Region
Central/ Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

KEY QUESTIONS ANSWERED IN THIS REPORT
How has the Japan cardiac biomarkers market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan cardiac biomarkers market?
What is the breakup of the Japan cardiac biomarkers market on the basis of type?
What is the breakup of the Japan cardiac biomarkers market on the basis of location of testing?
What is the breakup of the Japan cardiac biomarkers market on the basis of application?
What are the various stages in the value chain of the Japan cardiac biomarkers market?
What are the key driving factors and challenges in the Japan cardiac biomarkers?
What is the structure of the Japan cardiac biomarkers market and who are the key players?
What is the degree of competition in the Japan cardiac biomarkers market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Cardiac Biomarkers Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Cardiac Biomarkers Market Landscape

5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)

6 Japan Cardiac Biomarkers Market - Breakup by Type

6.1 Troponins (T and I)
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2020-2025)
- 6.1.3 Market Forecast (2026-2034)
6.2 Myocardial Muscle Creatine Kinase (CK-MB)
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2020-2025)
- 6.2.3 Market Forecast (2026-2034)
6.3 Myoglobin
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2020-2025)
- 6.3.3 Market Forecast (2026-2034)
6.4 Brain Natriuretic Peptide (BNPs) or NT-proBNP
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2020-2025)
- 6.4.3 Market Forecast (2026-2034)
6.5 Ischemia Modified Albumin (IMA)
- 6.5.1 Overview
- 6.5.2 Historical and Current Market Trends (2020-2025)
- 6.5.3 Market Forecast (2026-2034)
6.6 Others
- 6.6.1 Historical and Current Market Trends (2020-2025)
- 6.6.2 Market Forecast (2026-2034)

7 Japan Cardiac Biomarkers Market - Breakup by Location of Testing

7.1 Laboratory Testing
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2020-2025)
- 7.1.3 Market Forecast (2026-2034)
7.2 Point of Care Testing
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2020-2025)
- 7.2.3 Market Forecast (2026-2034)

8 Japan Cardiac Biomarkers Market - Breakup by Application

8.1 Myocardial Infarction
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2020-2025)
- 8.1.3 Market Forecast (2026-2034)
8.2 Congestive Heart Failure
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2020-2025)
- 8.2.3 Market Forecast (2026-2034)
8.3 Acute Coronary Syndrome
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2020-2025)
- 8.3.3 Market Forecast (2026-2034)
8.4 Atherosclerosis
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2020-2025)
- 8.4.3 Market Forecast (2026-2034)
8.5 Others
- 8.5.1 Historical and Current Market Trends (2020-2025)
- 8.5.2 Market Forecast (2026-2034)

9 Japan Cardiac Biomarkers Market - Breakup by Region

9.1 Kanto Region
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2020-2025)
- 9.1.3 Market Breakup by Type
- 9.1.4 Market Breakup by Location of Testing
- 9.1.5 Market Breakup by Application
- 9.1.6 Key Players
- 9.1.7 Market Forecast (2026-2034)
9.2 Kansai/Kinki Region
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2020-2025)
- 9.2.3 Market Breakup by Type
- 9.2.4 Market Breakup by Location of Testing
- 9.2.5 Market Breakup by Application
- 9.2.6 Key Players
- 9.2.7 Market Forecast (2026-2034)
9.3 Central/ Chubu Region
- 9.3.1 Overview
- 9.3.2 Historical and Current Market Trends (2020-2025)
- 9.3.3 Market Breakup by Type
- 9.3.4 Market Breakup by Location of Testing
- 9.3.5 Market Breakup by Application
- 9.3.6 Key Players
- 9.3.7 Market Forecast (2026-2034)
9.4 Kyushu-Okinawa Region
- 9.4.1 Overview
- 9.4.2 Historical and Current Market Trends (2020-2025)
- 9.4.3 Market Breakup by Type
- 9.4.4 Market Breakup by Location of Testing
- 9.4.5 Market Breakup by Application
- 9.4.6 Key Players
- 9.4.7 Market Forecast (2026-2034)
9.5 Tohoku Region
- 9.5.1 Overview
- 9.5.2 Historical and Current Market Trends (2020-2025)
- 9.5.3 Market Breakup by Type
- 9.5.4 Market Breakup by Location of Testing
- 9.5.5 Market Breakup by Application
- 9.5.6 Key Players
- 9.5.7 Market Forecast (2026-2034)
9.6 Chugoku Region
- 9.6.1 Overview
- 9.6.2 Historical and Current Market Trends (2020-2025)
- 9.6.3 Market Breakup by Type
- 9.6.4 Market Breakup by Location of Testing
- 9.6.5 Market Breakup by Application
- 9.6.6 Key Players
- 9.6.7 Market Forecast (2026-2034)
9.7 Hokkaido Region
- 9.7.1 Overview
- 9.7.2 Historical and Current Market Trends (2020-2025)
- 9.7.3 Market Breakup by Type
- 9.7.4 Market Breakup by Location of Testing
- 9.7.5 Market Breakup by Application
- 9.7.6 Key Players
- 9.7.7 Market Forecast (2026-2034)
9.8 Shikoku Region
- 9.8.1 Overview
- 9.8.2 Historical and Current Market Trends (2020-2025)
- 9.8.3 Market Breakup by Type
- 9.8.4 Market Breakup by Location of Testing
- 9.8.5 Market Breakup by Application
- 9.8.6 Key Players
- 9.8.7 Market Forecast (2026-2034)

10 Japan Cardiac Biomarkers Market - Competitive Landscape

10.1 Overview
10.2 Market Structure
10.3 Market Player Positioning
10.4 Top Winning Strategies
10.5 Competitive Dashboard
10.6 Company Evaluation Quadrant

11 Profiles of Key Players

11.1 Company A
- 11.1.1 Business Overview
- 11.1.2 Services Offered
- 11.1.3 Business Strategies
- 11.1.4 SWOT Analysis
- 11.1.5 Major News and Events
11.2 Company B
- 11.2.1 Business Overview
- 11.2.2 Services Offered
- 11.2.3 Business Strategies
- 11.2.4 SWOT Analysis
- 11.2.5 Major News and Events
11.3 Company C
- 11.3.1 Business Overview
- 11.3.2 Services Offered
- 11.3.3 Business Strategies
- 11.3.4 SWOT Analysis
- 11.3.5 Major News and Events
11.4 Company D
- 11.4.1 Business Overview
- 11.4.2 Services Offered
- 11.4.3 Business Strategies
- 11.4.4 SWOT Analysis
- 11.4.5 Major News and Events
11.5 Company E
- 11.5.1 Business Overview
- 11.5.2 Services Offered
- 11.5.3 Business Strategies
- 11.5.4 SWOT Analysis
- 11.5.5 Major News and Events

12 Japan Cardiac Biomarkers Market - Industry Analysis

12.1 Drivers, Restraints, and Opportunities
- 12.1.1 Overview
- 12.1.2 Drivers
- 12.1.3 Restraints
- 12.1.4 Opportunities
12.2 Porters Five Forces Analysis
- 12.2.1 Overview
- 12.2.2 Bargaining Power of Buyers
- 12.2.3 Bargaining Power of Suppliers
- 12.2.4 Degree of Competition
- 12.2.5 Threat of New Entrants
- 12.2.6 Threat of Substitutes
12.3 Value Chain Analysis